These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 9520251)

  • 1. Discordance between malignant hyperthermia susceptibility and RYR1 mutation C1840T in two Scandinavian MH families exhibiting this mutation.
    Fagerlund TH; Ording H; Bendixen D; Islander G; Ranklev Twetman E; Berg K
    Clin Genet; 1997 Dec; 52(6):416-21. PubMed ID: 9520251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family.
    Serfas KD; Bose D; Patel L; Wrogemann K; Phillips MS; MacLennan DH; Greenberg CR
    Anesthesiology; 1996 Feb; 84(2):322-9. PubMed ID: 8602662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
    Robinson RL; Brooks C; Brown SL; Ellis FR; Halsall PJ; Quinnell RJ; Shaw MA; Hopkins PM
    Hum Mutat; 2002 Aug; 20(2):88-97. PubMed ID: 12124989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of contracture tests with halothane, caffeine, and ryanodine depend on different malignant hyperthermia-associated ryanodine receptor gene mutations.
    Fiege M; Wappler F; Weisshorn R; Ulrich Gerbershagen M; Steinfath M; Schulte Am Esch J
    Anesthesiology; 2002 Aug; 97(2):345-50. PubMed ID: 12151923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation screening in the ryanodine receptor 1 gene (RYR1) in patients susceptible to malignant hyperthermia who show definite IVCT results: identification of three novel mutations.
    Rueffert H; Olthoff D; Deutrich C; Meinecke CD; Froster UG
    Acta Anaesthesiol Scand; 2002 Jul; 46(6):692-8. PubMed ID: 12059893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of discordance between genotype and phenotype in a malignant hyperthermia family.
    Fortunato G; Carsana A; Tinto N; Brancadoro V; Canfora G; Salvatore F
    Eur J Hum Genet; 1999; 7(4):415-20. PubMed ID: 10352931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of a positive malignant hyperthermia (MH) disposition without the in vitro contracture test in families carrying the RYR1 Arg614Cys mutation.
    Rueffert H; Olthoff D; Deutrich C; Froster UG
    Clin Genet; 2001 Aug; 60(2):117-24. PubMed ID: 11553045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [In vitro contracture test and gene typing in diagnosing malignant hyperthermia. Each as an appropriate complement to the other method].
    Rüffert H; Olthoff D; Deutrich C; Thamm B; Froster U
    Anaesthesist; 2000 Feb; 49(2):113-20. PubMed ID: 10756965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree.
    Brown RL; Pollock AN; Couchman KG; Hodges M; Hutchinson DO; Waaka R; Lynch P; McCarthy TV; Stowell KM
    Hum Mol Genet; 2000 Jun; 9(10):1515-24. PubMed ID: 10888602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotype-phenotype comparison of the Swiss malignant hyperthermia population.
    Girard T; Urwyler A; Censier K; Mueller CR; Zorzato F; Treves S
    Hum Mutat; 2001 Oct; 18(4):357-8. PubMed ID: 11668625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of a novel ryanodine receptor subtype 1 mutation (R328W) in a malignant hyperthermia family by sequencing of a leukocyte transcript.
    Loke JC; Kraev N; Sharma P; Du G; Patel L; Kraev A; MacLennan DH
    Anesthesiology; 2003 Aug; 99(2):297-302. PubMed ID: 12883402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discordance, in a malignant hyperthermia pedigree, between in vitro contracture-test phenotypes and haplotypes for the MHS1 region on chromosome 19q12-13.2, comprising the C1840T transition in the RYR1 gene.
    Deufel T; Sudbrak R; Feist Y; Rübsam B; Du Chesne I; Schäfer KL; Roewer N; Grimm T; Lehmann-Horn F; Hartung EJ
    Am J Hum Genet; 1995 Jun; 56(6):1334-42. PubMed ID: 7762556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homozygous and heterozygous Arg614Cys mutations (1840C-->T) in the ryanodine receptor gene co-segregate with malignant hyperthermia susceptibility in a German family.
    Rueffert H; Olthoff D; Deutrich C; Thamm B; Froster UG
    Br J Anaesth; 2001 Aug; 87(2):240-5. PubMed ID: 11493496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing?
    Robinson RL; Anetseder MJ; Brancadoro V; van Broekhoven C; Carsana A; Censier K; Fortunato G; Girard T; Heytens L; Hopkins PM; Jurkat-Rott K; Klinger W; Kozak-Ribbens G; Krivosic R; Monnier N; Nivoche Y; Olthoff D; Rueffert H; Sorrentino V; Tegazzin V; Mueller CR
    Eur J Hum Genet; 2003 Apr; 11(4):342-8. PubMed ID: 12700608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional characterization of the RYR1 mutation p.Arg4737Trp associated with susceptibility to malignant hyperthermia.
    Johannsen S; Treves S; Müller CR; Mögele S; Schneiderbanger D; Roewer N; Schuster F
    Neuromuscul Disord; 2016 Jan; 26(1):21-5. PubMed ID: 26631338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic variation in RYR1 and malignant hyperthermia phenotypes.
    Carpenter D; Robinson RL; Quinnell RJ; Ringrose C; Hogg M; Casson F; Booms P; Iles DE; Halsall PJ; Steele DS; Shaw MA; Hopkins PM
    Br J Anaesth; 2009 Oct; 103(4):538-48. PubMed ID: 19648156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotyping malignant hyperthermia susceptibility by measuring halothane-induced changes in myoplasmic calcium concentration in cultured human skeletal muscle cells.
    Girard T; Treves S; Censier K; Mueller CR; Zorzato F; Urwyler A
    Br J Anaesth; 2002 Oct; 89(4):571-9. PubMed ID: 12393358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in vitro contracture test.
    Brandt A; Schleithoff L; Jurkat-Rott K; Klingler W; Baur C; Lehmann-Horn F
    Hum Mol Genet; 1999 Oct; 8(11):2055-62. PubMed ID: 10484775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multigenerational Brazilian family with malignant hyperthermia and a novel mutation in the RYR1 gene.
    Matos AR; Sambuughin N; Rumjanek FD; Amoedo ND; Cunha LB; Zapata-Sudo G; Sudo RT
    Braz J Med Biol Res; 2009 Dec; 42(12):1218-24. PubMed ID: 19918671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sevoflurane is less sensitive than halothane for in vitro detection of malignant hyperthermia susceptibility.
    Johannsen S; Klingler W; Schneiderbanger D; Heiderich S; Roewer N; Schuster F
    Acta Anaesthesiol Scand; 2013 Oct; 57(9):1161-6. PubMed ID: 23957432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.